Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: The mTOR inhibitor Everolimus is approved for the treatment of PanNET and no predictive biomarker is available. mTOR is a central node controlling mitochondrial and aerobic glycolytic metabolisms.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Cros J, Bucau M, Raffenne J, Soukeur M, Dumont F,
Keywords: mTOR, everolimus, pancreatic NET, metabolism,
Introduction: mTOR inhibitor Everolimus is approved for the treatment of well-differentiated PNET. The heterogeneity of the response rate and the potential toxicity warrant predictive biomarkers.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: CROS J
Authors: Bucau M, Cros J, Raffenne J, Rebours V, Palazzo M,
Keywords: PNET, everolimus, predictive biomarkers,
Introduction: The 18F-FDG uptake assessed by PET/CT is correlated to prognosis in most tumors.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author:
Authors: Bucau M, Laurent-Bellue A, Cros J, Hentic O, Rebours V,
Keywords: Neuroendocrine tumors, PET-scan, 18-FDG, Ki67, VHL, metabolism,
Introduction: Patients with PNET might benefit from new therapeutic approaches acting on the mTOR signaling pathway. Culture of precision-cut slices could allow testing these molecules in human tumors, allowing personalized treatments.
Conference: 11th Annual ENETSConcerence (2014)
Presenting Author:
Authors: Bucau M, Cros J, Rebours V, Albuquerque M, Paradis V,
Keywords: pancreas, targeted therapies, tissue culture, neuroendocrine tumors,